Clinical study of Compound Congrong Yizhi Capsule in treating mild to moderate Alzheimer's disease
10.3969/j.issn.1006.1006-2157.2024.08.017
- VernacularTitle:复方苁蓉益智胶囊治疗轻中度阿尔茨海默病患者的临床疗效研究
- Author:
Mengyuan LI
1
;
Jinping SUN
;
Wei SUN
;
Zhanjun ZHANG
;
He LI
Author Information
1. 北京师范大学 北京 100091
- Keywords:
Compound Congrong Yizhi Capsule;
mild to moderate Alzheimer's disease;
cognitive function;
clinical efficacy;
preventive treatment of disease
- From:
Journal of Beijing University of Traditional Chinese Medicine
2024;47(8):1145-1151
- CountryChina
- Language:Chinese
-
Abstract:
Objective We aimed to observe the clinical efficacy and safety of Compound Congrong Yizhi Capsule in subjects with mild to moderate Alzheimer's disease (AD). Methods A total of 65 subjects with mild to moderate AD who visited the Affiliated Hospital of Qingdao University and Xuanwu Hospital of Capital Medical University from February 2023 to February 2024 were selected and divided into the Compound Congrong Yizhi Capsule group (40 cases) and the Donepezil Hydrochloride group (25 cases) for a 6-month treatment. The primary outcome measures included the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score and Auditory Verbal Learning Test (AVLT) score. Secondary outcome measures included the Mini-Mental State Examination (MMSE),Activities of Daily Living (ADL),Rey-Osterrieth Complex Figure Test (ROCFT),Trail Making Test (TMT),Verbal Fluency Test (VFT),Symbol Digit Modalities Test (SDMT),Digital Span Test (DST),Clock Drawing Test (CDT),and Boston Naming Test (BNT) scores,as well as clinical biochemical indicators including blood lipids,blood glucose,liver and kidney function. Results Compared with the Donepezil Hydrochloride group after treatment,subjects in the Compound Congrong Yizhi Capsule group showed an increase in ADAS-Cog and AVLT-total scores,and a decrease in MMSE,Rey-Osterrieth Complex Figure Copy Test,and CDT scores (P<0.05). Additionally,there was an increase in alanine aminotransferase (ALT),blood urea nitrogen(BUN),and total bilirubin (TBIL) levels,and a decrease in indirect bilirubin (IBIL) levels (P<0.05).Conclusion Compound Congrong Yizhi Capsule exerts a regulatory effect on cognitive function in subjects with AD,especially in the cognitive domains of episodic memory and visual-spatial processing ability. It also improves certain clinical indicators such as ALT,BUN,TBIL,and IBIL. This suggests that the early intervention with Compound Congrong Yizhi Capsule in AD can effectively improve symptoms,delay disease progression,and fully embody the concept of traditional Chinese medicine's preventive approach to illness.
